Invasive Aspergillosis: Current Strategies for Diagnosis and Management

Infectious Disease Clinics of North America

Volumn 30, Issue 1, 2016, Pages 125-142

  Cadena, Jose ^a   Thompson, George R ^b   Patterson, Thomas F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aspergilloma; Aspergillosis; Chronic cavitary aspergillosis; Invasive pulmonary aspergillosis; Resistance

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ECHINOCANDIN; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL RESISTANCE; ASPERGILLOMA; ASPERGILLOSIS; ASPERGILLOSIS RHINOSINUSITIS; ASPERGILLUS; ASPERGILLUS OSTEOMYELITIS; CAUSAL ATTRIBUTION; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CLINICAL FEATURE; DISEASE SURVEILLANCE; DRUG EFFECT; HIGH RISK PATIENT; HOST SUSCEPTIBILITY; HUMAN; INVASIVE ASPERGILLOSIS; MORTALITY; NONHUMAN; OCULAR ASPERGILLOSIS; REVIEW; TRACHEOBRONCHIAL ASPERGILLOSIS; TREATMENT PLANNING; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MICROBIOLOGY; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS;

EID: 84958172769     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.10.015     Document Type: Review

References (94)

1. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(3):327-360.
2. Pagano L., Akova M., Dimopoulos G., et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011, 66(Suppl 1):i5-i14.
3. Summerbell R. Ascomycetes. Aspergillus, fusarium, sporothrix, piedraia, and their relatives. Pathogenic fungi in humans and animals 2003, 237-498. Marcel Dekker, New York. 2nd edition. D.H. Howard (Ed.).
4. Balajee S.A., Houbraken J., Verweij P.E., et al. Aspergillus species identification in the clinical setting. Stud Mycol 2007, 59:39-46.
5. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000, 79(4):250-260.
6. Balajee S.A., Nickle D., Varga J., et al. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell 2006, 5(10):1705-1712.
7. Klich M., Pitt J. A laboratory guide to common Aspergillus species and their teleomorphs 1988, Commonwealth Scientific and Industrial Research Organization, North Ryde, New South Wales, (Australia).
8. O'Gorman C.M., Fuller H.T., Dyer P.S. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 2009, 457(7228):471-474.
9. Pitt J.I., Samson R.A. Nomenclatural considerations in naming species of Aspergillus and its teleomorphs. Stud Mycol 2007, 59:67-70.
10. Nedel W.L., Pasqualotto A.C. Treatment of infections by cryptic Aspergillus species. Mycopathologia 2014, 178(5-6):441-445.
11. Howard S.J., Harrison E., Bowyer P., et al. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother 2011, 55(10):4802-4809.
12. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of multicenter prospective antifungal therapy (path) alliance registry. Clin Infect Dis 2009, 48(3):265-273.
13. Panackal A.A., Li H., Kontoyiannis D.P., et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010, 50(12):1588-1597.
14. Nucci M., Anaissie E. Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation-focus on aspergillosis. Clin Chest Med 2009, 30(2):295-306. vii.
15. Nucci M., Portugal R.D., Garnica M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol 2009, 27(23):3849-3854.
16. Patterson J.E., Peters J., Calhoon J.H., et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000, 2(1):22-28.
17. Singh N., Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005, 18(1):44-69.
18. Paterson D.L., Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999, 78(2):123-138.
19. Denning D.W. Aspergillosis in "nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004, 170(6):580-581.
20. Lat A., Bhadelia N., Miko B., et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16(6):971-973.
21. Meersseman W., Vandecasteele S.J., Wilmer A., et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170(6):621-625.
22. Koulenti D., Garnacho-Montero J., Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis 2014, 27(2):174-183.
23. Warris A., Bjorneklett A., Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001, 344(14):1099-1100.
24. Cohen M.S., Isturiz R.E., Malech H.L., et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981, 71(1):59-66.
25. Chai L.Y., de Boer M.G., van der Velden W.J., et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-and susceptibility to invasive aspergillosis. J Infect Dis 2011, 203(5):736-743.
26. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359(17):1766-1777.
27. Denning D.W., Riniotis K., Dobrashian R., et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review. Clin Infect Dis 2003, 37(Suppl 3):S265-S280.
28. Greenberger P.A., Bush R.K., Demain J.G., et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2014, 2(6):703-708.
29. Binder R.E., Faling L.J., Pugatch R.D., et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982, 61(2):109-124.
30. Gefter W.B., Weingrad T.R., Epstein D.M., et al. "Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology 1981, 140(2):313-321.
31. Hope W.W., Walsh T.J., Denning D.W. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005, 43(Suppl 1):S207-S238.
32. Felton T.W., Baxter C., Moore C.B., et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010, 51(12):1383-1391.
33. Gerson S.L., Talbot G.H., Hurwitz S., et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984, 100(3):345-351.
34. Wald A., Leisenring W., van Burik J.A., et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175(6):1459-1466.
35. Thompson G.R., Patterson T.F. Pulmonary aspergillosis: recent advances. Semin Respir Crit Care Med 2011, 32(6):673-681.
36. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26(4):781-803. [quiz: 804-5].
37. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19(1):253-259.
38. Greene R. The radiological spectrum of pulmonary aspergillosis. Med Mycol 2005, 43(Suppl 1):S147-S154.
39. Miceli M.H., Maertens J., Buve K., et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007, 110(1):112-120.
40. Baddley J.W., Andes D.R., Marr K.A., et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010, 50(12):1559-1567.
41. von Eiff M., Roos N., Schulten R., et al. Pulmonary aspergillosis: Early diagnosis improves survival. Respiration 1995, 62(6):341-347.
42. Denning D.W., Follansbee S.E., Scolaro M., et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324(10):654-662.
43. Kramer M.R., Denning D.W., Marshall S.E., et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991, 144(Pt 1):552-556.
44. Fernandez-Ruiz M., Silva J.T., San-Juan R., et al. Aspergillus tracheobronchitis: Report of 8 cases and review of the literature. Medicine (Baltimore) 2012, 91(5):261-273.
45. Thompson G.R., Patterson T.F. Fungal disease of the nose and paranasal sinuses. J Allergy Clin Immunol 2012, 129(2):321-326.
46. Chang C., Gershwin M.E., Thompson G.R. Fungal disease of the nose and sinuses: an updated overview. Curr Allergy Asthma Rep 2013, 13(2):152-161.
47. Duggal P., Wise S.K. Chapter 8: invasive fungal rhinosinusitis. Am J Rhinol Allergy 2013, 27(Suppl 1):S28-S30.
48. Prajna N.V., Krishnan T., Mascarenhas J., et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol 2013, 131(4):422-429.
49. Gabrielli E., Fothergill A.W., Brescini L., et al. Osteomyelitis caused by Aspergillus species: a review of 310 reported cases. Clin Microbiol Infect 2014, 20(6):559-565.
50. Munoz P., Alcala L., Sanchez Conde M., et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003, 75(3):326-329.
51. Horvath J.A., Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996, 100(2):171-178.
52. Herbrecht R., Letscher-Bru V., Oprea C., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002, 20(7):1898-1906.
53. Maertens J., Verhaegen J., Lagrou K., et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001, 97(6):1604-1610.
54. Verweij P.E., Mennink-Kersten M.A. Issues with galactomannan testing. Med Mycol 2006, 44(Suppl):179-183.
55. Duarte R.F., Sanchez-Ortega I., Cuesta I., et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014, 59(12):1696-1702.
56. Hope W.W., Petraitis V., Petraitiene R., et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 2010, 54(11):4879-4886.
57. Koo S., Bryar J.M., Baden L.R., et al. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010, 48(4):1255-1260.
58. Maertens J., Maertens V., Theunissen K., et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009, 49(11):1688-1693.
59. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004, 39(2):199-205.
60. Obayashi T., Yoshida M., Mori T., et al. Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995, 345(8941):17-20.
61. Aguado J.M., Vazquez L., Fernandez-Ruiz M., et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015, 60(3):405-414.
62. White P.L., Wingard J.R., Bretagne S., et al. Aspergillus polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis 2015, 61(8):1293-1303.
63. White P.L., Posso R.B., Barnes R.A. Analytical and Clinical Evaluation of the PathoNostics AsperGenius Assay for Detection of Invasive Aspergillosis and Resistance to Azole Antifungal Drugs during Testing of Serum Samples. J Clin Microbiol 2015, 53(7):2115-2121.
64. Caramalho R., Gusmao L., Lackner M., et al. SNaPAfu: A novel single nucleotide polymorphism multiplex assay for aspergillus fumigatus direct detection, identification, and genotyping in clinical specimens. PLoS One 2013, 8(10):e75968.
65. Wiederhold N.P., Patterson T.F. What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents. Curr Opin Infect Dis 2015, 28:539-545.
66. Lat A., Thompson G.R. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011, 4:43-53.
67. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6):408-415.
68. Eiden C., Peyriere H., Cociglio M., et al. Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007, 41(5):755-763.
69. Park W.B., Kim N.H., Kim K.H., et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012, 55(8):1080-1087.
70. Ashbee H.R., Barnes R.A., Johnson E.M., et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014, 69(5):1162-1176.
71. Alvarez-Lerma F., Allepuz-Palau A., Garcia M.P., et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 2008, 20(1):93-100.
72. Thompson G.R., Lewis J.S. Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol 2010, 6(1):83-94.
73. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356(4):335-347.
74. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4):348-359.
75. Dolton M.J., Ray J.E., Chen S.C., et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012, 56(11):5503-5510.
76. De Beule K., Van Gestel J. Pharmacology of itraconazole. Drugs 2001, 61(Suppl 1):27-37.
77. Andes D., Pascual A., Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53(1):24-34.
78. Thompson G.R., Wiederhold N.P. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010, 170(5):291-313.
79. Maertens J, Patterson TF, Rahav G, et al. A phase 3 randomized, double-blind trial evaluating isavuconazole vs voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE). 24th ECCMID. Barcelona, Spain, 10-13 May, 2014.
80. Miceli M.H., Kauffman C.A. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015, 61(10):1558-1565.
81. Bennett J.E. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 2006, 355(11):1154-1159.
82. Viscoli C., Herbrecht R., Akan H., et al. An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009, 64(6):1274-1281.
83. Kohno S., Izumikawa K., Ogawa K., et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010, 61(5):410-418.
84. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53(5):337-349.
85. Hiemenz J.W., Raad I.I., Maertens J.A., et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010, 29(11):1387-1394.
86. Kontoyiannis D.P., Ratanatharathorn V., Young J.A., et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009, 11(1):89-93.
87. Anderson T.M., Clay M.C., Cioffi A.G., et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 2014, 10(5):400-406.
88. Patterson T.F., Boucher H.W., Herbrecht R., et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005, 41(10):1448-1452.
89. Bates D.W., Su L., Yu D.T., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001, 32(5):686-693.
90. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44(10):1289-1297.
91. Marr K.A., Schlamm H.T., Herbrecht R., et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015, 162(2):81-89.
92. van der Linden J.W., Arendrup M.C., Warris A., et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015, 21(6):1041-1044.
93. Winston D.J., Bartoni K., Territo M.C., et al. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011, 17(4):507-515.
94. Maschmeyer G., Patterson T.F. Our 2014 approach to breakthrough invasive fungal infections. Mycoses 2014, 57(11):645-651.